Gastrointestinal adverse events were the most common, and treatment discontinuations increased with higher doses, reinforcing the importance of careful patient selection and shared decision-making
full weight loss effect at 68 weeks STEP-1 result / 14.9% mean body-weight loss with semaglutide 2.4 mg vs
P = .046)
Though people consume glutathione in the form of pills, you can try to increase its natural production in the body by consuming certain food items rich in amino acids
Why individual timelines vary dramatically Your baseline metabolism, body composition , insulin sensitivity, and dietary habits all influence how quickly you respond to semaglutide

Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
